National Comprehensive Cancer Network
- NCCN
Guidelines®- End User License Agreement
- NCCN Guidelines for
Treatment of Cancer by Site- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Anal Carcinoma
- Basal and Squamous Cell Skin Cancers
- Bladder Cancer
- Bone Cancer
- Breast Cancer
- Central Nervous System Cancers
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colon Cancer
- Dermatofibrosarcoma Protuberans
- Esophageal and Esophagogastric Junction Cancers
- Gastric Cancer
- NCCN Guidelines for Detection,
Prevention, & Risk Reduction - NCCN Guidelines for
Supportive Care - NCCN Guidelines for
Age Related Recommendations - NCCN Guidelines for Patients®
- International Adaptations & Translations
- NCCN Pocket Guidelines
- NCCN Disclosure Policies &
Potential Conflicts of Interest - Licensing and Permissions
- Stay up-to-date with
NCCN Flash Updates™ - NCCN Guidelines Apps
- NCCN
Compendia- End User License Agreement
- NCCN Compendium®
- NCCN Biomarkers Compendium™
- Subscribe to the NCCN Compendia
- Licensing and Permissions
- Subscriptions
& Products- NCCN Compendium
- NCCN Biomarkers Compendium
- NCCN Templates
- Combination Subscriptions
- NCCN Flash Updates™
- NCCN Flash Updates™ Coupons
- NCCN Trends™ Surveys & Data
- NCCN Academy Video Modules
- NCCN eBulletin Newsletter
- NCCN Health Information Technology Licensees
- JNCCN — Journal of the National Comprehensive Cancer Network
- Advertising Opportunities
- NCCN Online Catalog
- Clinical & Business
Resources- Members Only
- NCCN Corporate Council
- NCCN Academy
- NCCN Insights: Analytics, Research & Consulting
- NCCN Resource Tool: REMS
- NCCN Collaboration with the National Business Group on Health
- NCCN Virtual Reimbursement Resource Room
- NCCN Health Information Technology Licensees
- NCCN Oncology Policy Program White Papers
- NCCN Oncology Research Program (ORP)
- ORP Recent News
- NCCN ORP Affiliate Research Project
- ORP Scientific Publications
- ORP Investigator Steering Committee
- ORP Testimonials
- Clinical Trials at NCCN Member Institutions
- Find ORP Funded Clinical Trials at NCCN Member Institutions
- NCCN Specialized Imaging Research Consortium™ (SIRC)
- NCCN ORP Disclosure Policy
- NCCN ORP for Industry
- NCCN Informed Consent Language Database
- NCCN Content Policies
- Patient
Resources- NCCN Guidelines for Patients®
- NCCN Website for Patients and
Caregivers - NCCN.com - Find an NCCN Member Institution
- Find an NCCN Cancer Center Near You
- Information on Patient Assistance & Reimbursement Help
- NCCN Virtual Reimbursement Resource Room Guide
- Find Clinical Trials
- NCCN Foundation
- Donate to the NCCN Foundation
About NCCN
NCCN Guidelines™ and NCCN Compendium™ Updated
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Testicular Cancer. These NCCN Guidelines™ are currently available as Version 2.2010.
The TNM Staging System for Testicular Cancer has been updated based on the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual.
The Discussion section of the NCCN Guidelines™ for Testicular Cancer has also been updated.
NCCN has published the following updates to the Neuroendocrine Tumors chapter of the NCCN Drugs & Biologics Compendium (NCCN Compendium™) to reflect updates to the 2010 version of the corresponding NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™):
Everolimus and sunitinib have been added to the list of agents used in the management of metastatic islet cell tumors, both with a category 2B designation.
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved